Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

Flyduck schreef op 7 december 2017 09:29:

Ik heb het idee dat veel gokkers die in pharming zitten nu overstappen op bitcoin

quote:

Flyduck schreef op 7 december 2017 09:29:

Ik heb het idee dat veel gokkers die in pharming zitten nu overstappen op bitcoin

quote:

Arie40 schreef op 6 december 2017 20:52:

[...]

Dank voor je reactie!

Kom Voda zijn verhaal nog niet tegen . Heb van 810 tot 834 teruggekeken. Kijk morgen even verder terug.

Karen en anderen, bedankt voor jullie bezorgdheid. Voor die van mij en beginnende beleggers. Ik zat te denken om 30k te lenen. Bij een eigen vermogen van ruim een ton. En een ton overwaarde in mijn woning erboven op. Dan kan ik nooit keihard op mijn bakkes gaan dacht ik zo. Maar of ik 5% of eerder 50% op jaarbasis moet betalen, geen idee nog. Meer dan 10% ga ik niet betalen .

quote:

Madebeliefje schreef op 7 december 2017 09:59:

[...]

Wat dacht je van BAM, tjeemig wat een overtrokken reactie is daar geweest.

quote:

C200 schreef op 7 december 2017 10:05:

Koersdoelverhoging First Berlin Van 1,50 naar 1,70

First Berlin – Pharming Group NV Research Update (07/12/2017)
07 Dec 2017 By First Berlin Equity Research News
First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and increased the price target from EUR 1.50 to EUR 1.70.

Abstract
Several factors have conjoined to produce accelerating sales growth and a jump in the Pharming share price of over 260% since June. First, the sales force built up during H1/17 following the acquisition of full US Ruconest commercialisation rights in late 2016 reached full effectiveness during the third quarter. Second, an article in The Lancet highlighting Ruconests excellent phase II results in hereditary angioedema (HAE) prophylaxis was published a few weeks before the onset of a shortage of Shire's Cinryze - the market leader in this indication. Then, in September, Pharming announced plans to present an SBLA (Supplemental Biologics License Application) for Ruconest to the FDA for review with a view to expanding the drug's indication in HAE from acute attacks to prophylaxis. The SBLA, which was submitted last week, strengthens our confidence that Ruconest will be approved for HAE prophylaxis without a phase III trial and that first revenues in this indication will be generated in 2019. Q3/17 was a breakthrough quarter for Pharming. Revenue of €26.1m was 69% above Q1/17 and 72% above Q2/17 while EBIT at €8.5m was more than double the H1/17 figure of €4.2m. Management guidance for Q4/17 is for a "significant increase" in revenue relative to Q3/17 due in part to the Cinryze shortage. However, even assuming an end to the Cinryze shortage in 2018, we model 52.9% revenue growth in 2018 vs. 2017 based on Ruconest's newly raised profile on the US market, and its low side effect burden relative to competitors. We have raised our 2018 sales and EBIT forecasts by 52% and 130% respectively on our last study of 14 September and now see fair value for the stock at €1.70 (previously €1.50). We maintain our Buy recommendation.
Filed Under: Research

firstberlin.com/first-berlin-pharming...

quote:

moneymaker_BX schreef op 7 december 2017 10:13:

Waarom staat dit advies nog niet op Binck?

quote:

C200 schreef op 7 december 2017 10:05:

Koersdoelverhoging First Berlin Van 1,50 naar 1,70

First Berlin – Pharming Group NV Research Update (07/12/2017)
07 Dec 2017 By First Berlin Equity Research News
First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and increased the price target from EUR 1.50 to EUR 1.70.

Abstract
Several factors have conjoined to produce accelerating sales growth and a jump in the Pharming share price of over 260% since June. First, the sales force built up during H1/17 following the acquisition of full US Ruconest commercialisation rights in late 2016 reached full effectiveness during the third quarter. Second, an article in The Lancet highlighting Ruconests excellent phase II results in hereditary angioedema (HAE) prophylaxis was published a few weeks before the onset of a shortage of Shire's Cinryze - the market leader in this indication. Then, in September, Pharming announced plans to present an SBLA (Supplemental Biologics License Application) for Ruconest to the FDA for review with a view to expanding the drug's indication in HAE from acute attacks to prophylaxis. [b]The SBLA, which was submitted last week, strengthens our confidence that Ruconest will be approved for HAE prophylaxis without a phase III trial and that first revenues in this indication will be generated in 2019.[/b] Q3/17 was a breakthrough quarter for Pharming. Revenue of €26.1m was 69% above Q1/17 and 72% above Q2/17 while EBIT at €8.5m was more than double the H1/17 figure of €4.2m. Management guidance for Q4/17 is for a "significant increase" in revenue relative to Q3/17 due in part to the Cinryze shortage. However, even assuming an end to the Cinryze shortage in 2018, we model 52.9% revenue growth in 2018 vs. 2017 based on Ruconest's newly raised profile on the US market, and its low side effect burden relative to competitors. We have raised our 2018 sales and EBIT forecasts by 52% and 130% respectively on our last study of 14 September and now see fair value for the stock at €1.70 (previously €1.50). We maintain our Buy recommendation.
Filed Under: Research

firstberlin.com/first-berlin-pharming...

quote:

moneymaker_BX schreef op 7 december 2017 10:19:

Er worden vieze spelletjes gespeeld met de koers
Op zo een prachtige Berlin advies/rapport zou je minimaal 10 cent moeten stijgen koersdoel 1.70

quote:

Moneyaw schreef op 7 december 2017 10:23:

Wat een aandeel.